Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

NYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Heston Blumenthal has revealed that he is taking the weight-loss drug Wegovy. The celebrity chef admitted his use of the drug ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a drug ...

Wegovy, a brand-name formulation of the GLP-1 receptor agonist semaglutide, received approval to treat adult obesity in 2021. An early study showed that patients taking semaglutide lost 15% of ...

Popular weight loss drugs like Wegovy and Ozempic could increase the risk of stomach paralysis as well as several other serious gastrointestinal conditions, according to a study published in JAMA.

Wegovy is designed to be taken once a week by self-injection. Patients start on the lowest dose, 0.25 milligrams, and move up to the maintenance dose, 2.4 milligrams, over the course of 16 weeks.